Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors

NCT06176989 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06176989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06176989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
March 4, 2024
Completion date
December 31, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced chondrosarcoma, locally advanced large-cell neuroendocrine carcinoma, locally advanced olfactory neuroblastoma, locally advanced sinonasal adenocarcinoma, locally advanced sinonasal undifferentiated carcinoma, metastatic chondrosarcoma, metastatic large-cell neuroendocrine carcinoma, metastatic olfactory neuroblastoma, metastatic sinonasal adenocarcinoma, metastatic sinonasal undifferentiated carcinoma